CXCL9 Informations sur la molécule
Molecule Name
C-X-C motif chemokine 9
Alias de la molécule
CMK, Humig, MIG, SCYB9, crg-10
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 1 Clinical
Alias de la cible
C-X-C motif chemokine 9，Gamma-interferon-induced monokine，Monokine induced by interferon-gamma (HuMIG; MIG)，Small-inducible cytokine B9，SCYB9，Crg-10，Humig，CMK，MIG，Monokine Induced By Gamma Interferon，Monokine Induced By Interferon-Gamma，Gamma-Interferon-Induced Monokine，Chemokine (C-X-C Motif) Ligand 9，Small-Inducible Cytokine B9，C-X-C Motif Chemokine 9，HuMIG
Contexte de la molécule
CXCL9 is a small cytokine belonging to the CXC chemokine family that is also known as monokine induced by gamma interferon (MIG). CXCL9 is a chemokine that plays a role in immune responses, it can induce chemotaxis, promote differentiation and proliferation of leukocytes, and cause tissue extravasation. CXCL9 regulates immune cell migration, differentiation and activation by binding to CXCR3 receptor, such as CTLs, NK cells, NKT cells and macrophages. CXCL9 also participates in Th1 polarization and IFN-γ response.
Demande de produit
Asset Licensing Opportunity
Resources
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd, University Of Oxford | Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |
Customer Reviews